Clinical upside Cebix is advancing Ersatta, a long-acting C-peptide replacement, in a Phase 2 trial for type 1 diabetes and microvascular complications, presenting a potential disease-modifying approach with a large addressable patient population.

Unmet need There are currently few treatments and no approved drugs targeting microvascular damage from diabetes, indicating a clear opportunity to position Ersatta as a novel therapeutic option for neuropathy, retinopathy, nephropathy, and autonomic neuropathy.

Funding runway With substantial funding of approximately $101 million and a revenue funnel under $1 million, there is financial runway to support clinical development, partnering discussions, and pre-commercial planning.

Targeted outreach The focus on C-peptide deficiency in type 1 and some type 2 patients suggests sales strategies should target endocrinologists, diabetologists, and specialty clinics addressing long-term microvascular complications.

Competitive positioning Position Ersatta as a disease-modifying replacement therapy rather than symptom management, emphasizing potential reversal of chronic complications to differentiate from therapies focused on glycemic control.